Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether it is safe to give phenformin with the standard
drug combination of one of 3 FDA-approved combinations of BRAF inhibitor + MEK inhibitor
which are standard treatments for patients with metastatic melanoma whose melanoma has a
mutation in a gene called BRAF.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Massachusetts General Hospital Weill Medical College of Cornell University